EMFLAZA CAN HELP HIM CREATE HIS OWN STORY
EMFLAZA® (deflazacort) is a corticosteroid that works through receptors in the body to effectively inhibit inflammation.1-3
Clinical studies demonstrated that, compared to placebo, EMFLAZA:
Delayed the loss of muscle strength of Duchenne patients.4
Improved the ability to accomplish tasks related to standing, climbing stairs, to run or walk 30 feet.4
Slowed the loss of muscle strength over time.4
Clinical studies demonstrate that deflazacort may help decrease the amount of time to complete daily tasks
Deflazacort was assessed against placebo for its effect on the amount of time it took a patient to stand up after lying down, to climb 4 stairs, to walk or run 30 feet, and to propel a wheelchair 30 feet. The tests favored deflazacort to placebo in 3 out of the 4 tests.4,5
Time for supine
Time to climb
Time to run or
walk 30 feet
Ready to talk with your healthcare provider about EMFLAZA?
We created a Patient Discussion Guide to make it easier to speak to your healthcare team about Duchenne. The guide includes important questions for you to ask to help you feel prepared and empowered as you establish a treatment plan for your child. Download and print a copy to bring to your next doctor's appointment.
1. Langhoff E, Olgaard K. In vitro immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells. Br J Clin Pharmacol. 1986;21(2):125-129. 2. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317-333. 3. Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1. 4. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123-2131. 5. EMFLAZA (deflazacort) Prescribing Information. South Plainfield, NJ: PTC Therapeutics, Inc.